| Shadana Maddox, PHARMD | |
|
1221 Mercantile Ln, Largo, MD 20774-5374 | |
| (301) 618-4200 | |
| Not Available |
| Full Name | Shadana Maddox |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1221 Mercantile Ln, Largo, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215436183 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 25351 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shadana Maddox, PHARMD 16523 Governor Bridge Rd Apt 207, Bowie, MD 20716-3671 Ph: (301) 641-7087 | Shadana Maddox, PHARMD 1221 Mercantile Ln, Largo, MD 20774-5374 Ph: (301) 618-4200 |
News Archive
In this post in the Results for Development Institute's "Center for Global Health R&D Policy Assessment" blog, Aarthi Rao, a program officer at the institute, examines whether corporate social responsibility (CSR) programs within Indian pharmaceutical companies can help fight neglected diseases.
Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.
Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 12,150,000 shares of its common stock, at a price of $1.46 per share, and 12,150 shares of its Series C Convertible Preferred Stock, at a price of $1,460 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization.
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.
› Verified 1 days ago
Baochau D. Bui, PHARM-D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1221 Mercantile Ln, Largo, MD 20774 Phone: 301-618-5880 | |
Jaeyeon Kim, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1221 Mercantile Ln, Largo, MD 20774 Phone: 301-618-5500 | |
Helene Akonji, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9701 Apollo Dr, Largo, MD 20774 Phone: 301-477-3367 | |
Angela Goodwin, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1221 Mercantile Ln, Infusion Pharmacy, Largo, MD 20774 Phone: 301-618-5880 Fax: 301-618-5912 | |
Dr. Lily Leu, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1221 Mercantile Ln, Largo, MD 20774 Phone: 301-618-5500 | |
Dr. Kush Patel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9810 Apollo Dr, Largo, MD 20774 Phone: 301-322-9027 |